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Modeling shows that the NS5A inhibitor daclatasvir has two
modes of action and yields a shorter estimate of the hepatitis
C virus half-life. Guedj J, Dahari H, Rong L, Sansone ND, Nettles
RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS. Proc Natl
Acad Sci U S A. 2013 Mar 5;110(10):3991–6. Copyright  2013.
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Abstract. The nonstructural 5A (NS5A) protein is a target for drug
development against hepatitis C virus (HCV). Interestingly, the
NS5A inhibitor daclatasvir (BMS-790052) caused a decrease in
serum HCV RNA levels by about two orders of magnitude within
6 h of administration. However, NS5A has no known enzymatic
functions, making it difﬁcult to understand daclatasvir’s mode of
action (MOA) and to estimate its antiviral effectiveness. Modeling
viral kinetics during therapy has provided important insights into
the MOA and effectiveness of a variety of anti-HCV agents. Here,
we show that understanding the effects of daclatasvir in vivo
requires a multiscale model that incorporates drug effects on the
HCV intracellular lifecycle, and we validated this approach with
in vitro HCV infection experiments. The model predicts that dacla-
tasvir efﬁciently blocks two distinct stages of the viral lifecycle,
namely viral RNA synthesis and virion assembly/secretion with
mean effectiveness of 99% and 99.8%, respectively, and yields a
more precise estimate of the serum HCV half-life, 45 min, i.e.,
around four times shorter than previous estimates. Intracellular
HCV RNA in HCV-infected cells treated with daclatasvir and the
HCV polymerase inhibitor NM107 showed a similar pattern of
decline. However, daclatasvir treatment led to an immediate and
rapid decline of extracellular HCV titers compared to a delayed
(6–9 h) and slower decline with NM107, conﬁrming an effect of
daclatasvir on both viral replication and assembly/secretion. The
multiscale modeling approach, validated with in vitro kinetic
experiments, brings a unique conceptual framework for under-Journal of Hepatology 20
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Chronic hepatitis affects nearly 3% of the world population [1].
The landscape of therapy for hepatitis C virus (HCV) infection,
where treatment was still suboptimal until recently, is changing
rapidly. Speciﬁc proteins involved in the replication of the virus
have been identiﬁed and targeted by drug development. Among
these, we can enumerate non-structural (NS) viral proteins with
known enzymatic functions, such as the NS3/4A protease [2,3],
and the NS5B polymerase [4,5] but also non-enzymatic targets
such as NS5A proteins [6]. The mode of action of HCV drugs tar-
geting these proteins is not always understood. For example, the
mode of action of Daclatasvir (BMS-790052), one of the most
promising and expected molecules identiﬁed as a potent NS5A
inhibitor, is not known [6,7]. This is related to the uncertain nat-
ure of the molecular mechanisms by which NS5A functions and
the absence of direct screening assays for NS5A function.
One means of uncovering an antiviral agent’s mode of action
is to analyze the kinetics of the response it generates using
mathematical modeling. This approach was initiated by Perelson
et al. in HIV by characterizing the decline in HIV during antiret-
roviral therapy [8,9] and it was then successfully applied to
understand HCV kinetics during therapy [10]. In these models,
the infected cell is treated as a ‘‘black box’’ that produces/
secretes virus particles, which then either are cleared or infect
new target cells, and the effect of treatment is to block virus
production from infected cells [10]. Clearly, one limitation of
these models is that it does not take into account the stages
of the (intracellular) viral lifecycle that are yet the main target
of DAAs. In a recent study published in PNAS, Guedj et al. intro-
duced a novel generation of models, called ‘‘multiscale models’’
that, in contrast to the standard model, takes into account the
dynamics of the intracellular viral RNA and identiﬁes some
essential stages of viral replication that can be affected by treat-
ment, namely virion assembly/secretion, viral RNA production,
and vRNA degradation (Fig. 1) [11].
This model was applied to the comparison of the viral kinetics
observed after initiation of three different classes of agents,
namely IFN, telaprevir (a protease inhibitor) and daclatasvir
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Fig. 1. Presentation of the standard and multi-scale model of HCV dynamics, and parameter estimates obtained to ﬁt data from patients treated with daclatasvir
[11]. In both models, T and I represent target and infected cells, respectively, and V represents virus. Target cells are created and die with constant rates, s and d,
respectively, and are infected by virus, V, with constant rate b. Infected cells, I, are lost with constant rate d, and virus, V, is cleared from serum with constant rate c. (A) The
standard model considers only the level of cell infection and virus in the serum. Treatment (parameters in red) acts by reducing the average number of virions produced by
infected cells from p to (1  e)p. Thus, e represents a global measure of antiviral effectiveness that does not distinguish the stages of intracellular viral replication that are
blocked by treatment. The main estimates are c = 23.3 d1, e = 0.997, d = 1.06 d1. (B) The multi-scale model was designed to account for essential features of intracellular
HCV RNA replication, R, i.e., production, degradation, and assembly/secretion with rates a, l, and q, respectively. The HCV RNA level within an infected cell (dashed circle) is
assumed to increase with time since infection and reach a steady state. Treatment (parameters in red) may block HCV RNA production with effectiveness ea and/or virion
assembly/secretion with effectiveness es, and/or enhance the degration rate of HCV RNA by a factor j. The main estimates after ﬁxing d = 0.14 d1, l = 1 d1, a = 40 d1 are
c = 22.3 d1, ea = 0.99, es = 0.998, q = 8.18 d1, jl = 1.46 d1. Figure reprinted from [11], Copyright  2013, National Academy of Science.
JOURNAL OF HEPATOLOGY(a NS5A inhibitor) and allowed to puzzle out the mode of action
of these drugs. The authors showed that the kinetics observed
were dependent on the stages of the viral lifecycle where these
drugs acted. While all three agents were found to have a high
effectiveness in blocking vRNA production, the reason why HCV
RNA declines so rapidly with daclatasvir was due to the fact that
daclatasvir, unlike IFN and telaprevir to a lower extent, was
extremely effective in blocking viral assembly/secretion, with
an effectiveness estimated to 99.8% (vs. 39.0% in IFN-treated
patients, p <1010; and 0.94 in telaprevir-treated patients,
p <106). As a consequence, the number of viruses newly secreted
after initiation of daclatasvir is minimal and thus the viral decline
observed in serum provides a good model to estimate HCV half-
life in serum. Using this approach, Guedj et al. could demonstrate
that the current estimate of 2.7 h derived from the analysis of
viral kinetics during IFN-based treatment were not accurate
and now estimate the mean serum half-life of HCV at 45 min.
Of note, if HCV half-life is about four times shorter than previ-
ously thought, it implies that, in order to maintain a given level
of virus, HCV production is also four times larger than initiallyJournal of Hepatology 2013thought. Thus the risk of generating mutations conferring drug
resistance is also larger than previously thought.
The dual mechanism of action of daclatasvir provides a basis
to explain why NS5A inhibitors may be good candidates for com-
bination with drugs with complementary mode of actions, such
as protease or polymerase inhibitors. Yet, these modeling efforts
were based on the analysis of viral kinetics after one single dose
of daclatasvir, and important questions on the implications of this
dual mode of action remain to be solved. In particular, it is still
unclear whether that plays any role in improving the genetic bar-
rier to resistance and how this rapid initial viral decline translates
into the long-term viral decline. Clearly, further studies with
repeated doses of daclatasvir will be needed to study whether
blocking assembly/secretion accelerates only the initial viral
decline or also contributes to a faster elimination of the virus in
the long run that may allow for shorter treatment duration.
The speed of development of drugs to treat HCV infection is
unprecedented and new drugs with high potency, low side effects
and requiring short treatment duration are emerging. In this con-
text, mathematical modeling as the one performed by Guedj et al.vol. 59 j 1346–1348 1347
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is a promising tool to better understand the mechanism of action
of new DAAs, such as NS5A and NS5B inhibitors, or a new gener-
ation of antiprotease inhibitors [12], rationalizing the combina-
tion of these agents and eventually selecting agents with
complementary modes of action.Conﬂict of interest
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